Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chengdu Maxvax Bio Raises $40 Million for Vaccines and Immunotherapies

publication date: Mar 8, 2024

Chengdu Maxvax Biotechnology raised $40 million in a Series C financing round to advance its portfolio of seven vaccines, two of which are in clinical trials. The company develops innovative vaccines and immunotherapies to prevent and treat infectious diseases and cancer. Maxvax, which has five subsidiaries with over 300 employees, was founded in 2016. The company applies its three platforms -- adjuvant, recombinant protein and mRNA technology – to develop novel products. The company has been recognized as a national high-tech enterprise. The C round was funded exclusively by the Shenzhen Capital Group. More detail....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital